Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes

被引：6

作者：

Standl, Eberhard ^{[1
]}

机构：

[1] Munich Helmholtz Ctr, Munich Diabet Res Grp, DE-85764 Munich, Germany

来源：

DIABETES & VASCULAR DISEASE RESEARCH | 2013年 / 10卷 / 02期

关键词：

Type; 2; diabetes; cardiovascular disease; statins; fibrates; ezetimibe; nicotinic acid; CORONARY-HEART-DISEASE; POLYUNSATURATED FATTY-ACIDS; LOWERING LDL CHOLESTEROL; BLOOD-PRESSURE CONTROL; CHRONIC KIDNEY-DISEASE; UKPDS RISK ENGINE; GISSI-HF TRIAL; MYOCARDIAL-INFARCTION; SUBGROUP ANALYSIS; DOUBLE-BLIND;

D O I：

10.1177/1479164112448876

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diabetes is a significant risk factor for the development of cardiovascular disease (CVD), particularly in the presence of high blood pressure, poor glycaemic control and high total cholesterol. While efforts to control blood pressure or blood glucose beyond levels considered 'normal' in patients with diabetes have not produced the expected reduction in CVD, treatment with statins to reduce levels of low-density lipoprotein cholesterol (LDL-C) has been much more successful. However, many patients with diabetes who receive statins (even at high doses) remain at significant residual risk of CVD due to the presence of atherogenic dyslipidaemia. Markers of persisting risk include low levels of high-density lipoprotein cholesterol (HDL-C), high levels of triglycerides (TG) and LDL-C levels above target despite high-dose statin therapy. Combining statins with drugs that target HDL-C and TG, such as fibrates, niacin and omega-3 polyunsaturated fatty acid (PUFA) ethyl esters, may offer further protection from CVD in patients with diabetes.

引用

页码：99 / 114

页数：16

共 88 条

[1] Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
[2] [Anonymous], NIH STOPS CLIN TRIAL
[3] Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention - A Lescol Intervention Prevention Study (LIPS) substudy
Arampatzis, CA
Goedhart, D
Serruys, PW
Saia, F
Lemos, PA
de Feyter, P
[J]. AMERICAN HEART JOURNAL, 2005, 149 (02) : 329 - 335
[4] Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
Armitage, Jane
Bowman, Louise
Wallendszus, Karl
Bulbulia, Richard
Rahimi, Kazem
Haynes, Richard
Parish, Sarah
Peto, Richard
Collins, Rory
Meade, T.
Sleight, P.
Collins, R.
Armitage, J.
Bowman, L.
Parish, S.
Peto, R.
Barton, J.
Bray, C.
Wincott, E.
Dayanandan, R.
Clarke, R.
Graham, I.
Simpson, D.
Warlow, C.
Wilken, D.
Tobert, J.
Mushner, T.
Doll, R.
Wilhelmsen, L.
Fox, K.
Hill, C.
Sandercock, P.
Webster, J.
Henderson, J.
Nixon, A.
Lackie, S.
Thompson, J.
Brown, M.
Blackwood, S.
Morgan, M.
Rhoden, W.
Saeed, B.
Houghton, M.
Nicholson, A.
Simpson, C.
Hoburn, B.
Cooper, I.
Gallivan, A.
Pickerell, E.
Hancock, J.
[J]. LANCET, 2010, 376 (9753) : 1658 - 1669
[5] Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study
Assmann, G
Cullen, P
Schulte, H
[J]. CIRCULATION, 2002, 105 (03) : 310 - 315
[6] Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
Athyros, VG
Papageorgiou, AA
Mercouris, BR
Athyrou, VV
Symeonidis, AN
Basayannis, EO
Demitriadis, DS
Kontopoulos, AG
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) : 220 - 228
[7] Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus - A subgroup analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study
Athyros, VG
Papageorgiou, AA
Symeonidis, AN
Didangelos, TP
Pehlivanidis, AN
Bouloukos, VI
Mikhailidis, DP
[J]. ANGIOLOGY, 2003, 54 (06) : 679 - 690
[8] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Baigent, C.
Blackwell, L.
Emberson, J.
Holland, L. E.
Reith, C.
Bhala, N.
Peto, R.
Barnes, E. H.
Keech, A.
Simes, J.
Collins, R.
[J]. LANCET, 2010, 376 (9753) : 1670 - 1681
[9] The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Baigent, Colin
Landray, Martin J.
Reith, Christina
Emberson, Jonathan
Wheeler, David C.
Tomson, Charles
Wanner, Christoph
Krane, Vera
Cass, Alan
Craig, Jonathan
Neal, Bruce
Jiang, Lixin
Hooi, Lai Seong
Levin, Adeera
Agodoa, Lawrence
Gaziano, Mike
Kasiske, Bertram
Walker, Robert
Massy, Ziad A.
Feldt-Rasmussen, Bo
Krairittichai, Udom
Ophascharoensuk, Vuddidhej
Fellstrom, Bengt
Holdaas, Hallvard
Tesar, Vladimir
Wiecek, Andrzej
Grobbee, Diederick
de Zeeuw, Dick
Gronhagen-Riska, Carola
Dasgupta, Tanaji
Lewis, David
Herrington, William
Mafham, Marion
Majoni, William
Wallendszus, Karl
Grimm, Richard
Pedersen, Terje
Tobert, Jonathan
Armitage, Jane
Baxter, Alex
Bray, Christopher
Chen, Yiping
Chen, Zhengming
Hill, Michael
Knott, Carol
Parish, Sarah
Simpson, David
Sleight, Peter
Young, Alan
Collins, Rory
[J]. LANCET, 2011, 377 (9784) : 2181 - 2192
[10] The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia
Bays, Harold E.
Roth, Eli M.
McKenney, James M.
Kelly, Maureen T.
Thakker, Kamlesh M.
Setze, Carolyn M.
Obermeyer, Katie
Sleep, Darryl J.
[J]. DIABETES CARE, 2010, 33 (09) : 2113 - 2116

← 1 2 3 4 5 6 7 8 9 →